PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Pharmaceutics Année : 2021

PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases

Résumé

Treatment of neurodegenerative diseases has become one of the most challenging topics of the last decades due to their prevalence and increasing societal cost. The crucial point of the non-invasive therapeutic strategy for neurological disorder treatment relies on the drugs’ passage through the blood-brain barrier (BBB). Indeed, this biological barrier is involved in cerebral vascular homeostasis by its tight junctions, for example. One way to overcome this limit and deliver neuroprotective substances in the brain relies on nanotechnology-based approaches. Poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) are biocompatible, non-toxic, and provide many benefits, including improved drug solubility, protection against enzymatic digestion, increased targeting efficiency, and enhanced cellular internalization. This review will present an overview of the latest findings and advances in the PLGA NP-based approach for neuroprotective drug delivery in the case of neurodegenerative disease treatment (i.e., Alzheimer’s, Parkinson’s, Huntington’s diseases, Amyotrophic Lateral, and Multiple Sclerosis).
Fichier principal
Vignette du fichier
pharmaceutics-13-01042-1.pdf (1.96 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

inserm-03285083 , version 1 (13-07-2021)

Identifiants

Citer

Anthony Cunha, Alexandra Gaubert, Laurent Latxague, Benjamin Dehay. PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases. Pharmaceutics, 2021, 13 (7), pp.1042. ⟨10.3390/pharmaceutics13071042⟩. ⟨inserm-03285083⟩
16 Consultations
215 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More